World journal of hepatology · 2025
Effect of empagliflozin on fractional excretion of sodium in patients with cirrhosis and refractory ascites.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gao Yuan, Gao Yun-Yi, Shi Rong-Ya, Ji Dong, Wang Yu, Xu Liang, Wang Qi, Wu Meng-Hua, You Han-Lu, Bu Qiu-Shi, Dong Yi-Xi, Zhou Long-Zhen, Liu Wei, Song Qing-Kun, Han Ying, Wei Hou, Zhang Xin-Yu, Hu Zhong-Jie
Аннотация
BACKGROUND: Ascites is the most common complication of cirrhosis. Current pharmacological interventions, such as diuretics, often become ineffective in advanced stages due to diuretic resistance. Sodium-glucose co-transporter 2 (SGLT2) inhibitors have demonstrated potential in enhancing urinary sodium excretion and mitigating sodium-fluid retention. This study aims to evaluate the effects of SGLT2 inhibitors on the fractional excretion of sodium (FENa) in patients with cirrhotic ascites.
AIM: To determine whether adjunctive therapy with the SGLT2 inhibitor empagliflozin increases FENa compared with standard care alone in patients with cirrhosis and refractory ascites, and to evaluate its short-term safety profile.
METHODS: The effect of SGLT2 inhibitor empagliflozin on FENa in patients with cirrhosis and refractory ascites is a multicenter, open-label, randomized controlled trial. A total of 70 patients with refractory ascites secondary to cirrhosis will be enrolled and randomly assigned to receive either empagliflozin 10 mg daily plus standard care or standard care alone for 14 consecutive days. The primary outcome is the change in FENa from baseline to day 14. Secondary outcomes include 24-hour urinary sodium excretion, urine volume, ascites volume (assessed by ultrasound), body weight, and safety indicators. Exploratory outcomes include changes in components of the renin-angiotensin-aldosterone system.
RESULTS: This article reports the study protocol only. No participant data have been collected or analyzed for this manuscript.
CONCLUSION: This protocol evaluates whether empagliflozin, added to standard therapy, increases sodium excretion and reduces fluid overload in refractory ascites.
AIM: To determine whether adjunctive therapy with the SGLT2 inhibitor empagliflozin increases FENa compared with standard care alone in patients with cirrhosis and refractory ascites, and to evaluate its short-term safety profile.
METHODS: The effect of SGLT2 inhibitor empagliflozin on FENa in patients with cirrhosis and refractory ascites is a multicenter, open-label, randomized controlled trial. A total of 70 patients with refractory ascites secondary to cirrhosis will be enrolled and randomly assigned to receive either empagliflozin 10 mg daily plus standard care or standard care alone for 14 consecutive days. The primary outcome is the change in FENa from baseline to day 14. Secondary outcomes include 24-hour urinary sodium excretion, urine volume, ascites volume (assessed by ultrasound), body weight, and safety indicators. Exploratory outcomes include changes in components of the renin-angiotensin-aldosterone system.
RESULTS: This article reports the study protocol only. No participant data have been collected or analyzed for this manuscript.
CONCLUSION: This protocol evaluates whether empagliflozin, added to standard therapy, increases sodium excretion and reduces fluid overload in refractory ascites.